CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
A post-hoc pooled analysis of two placebo controlled phase 3 trials, Assessment of Weekly AdministRation of LY2189265 in Diabetes -1 and -5 (AWARD-1 and AWARD-5): dulaglutide compared with exenatide, sitagliptin, and placebo
DOI 10.1055/s-0034-1374980
Bibliografische Angaben
Nachweis in CareLit
Autor:innenO Adetunji, Z Skrivanek, A Tahbaz, S Bain, V Pechtner
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aim: To compare once weekly dulaglutide 1.5 mg and dulaglutide 0.75 mg with placebo at 26 weeks, and with sitagliptin 100 mg once daily (AWARD-5) and exenatide 10 µg twice daily (AWARD-1) at 26 and 52 weeks in patients with Type 2 diabetes with a mean baseline HbA1c of approximately 8%. Methods: Data from the dulaglutide 1.5 mg, dulaglutide 0.75 mg or placebo arms were pooled by treatment. Comparisons were made for…
Zitieren
Zitierempfehlung
O Adetunji, Z Skrivanek, A Tahbaz, S Bain, V Pechtner (2014) A post-hoc pooled analysis of two placebo controlled phase 3 trials, Assessment of Weekly AdministRation of LY2189265 in Diabetes -1 and -5 (AWARD-1 and AWARD-5): dulaglutide compared with exenatide, sitagliptin, and placebo. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1374980
Mit CareLit weiterarbeiten